PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2012; 12: 111.
Published online Mar 23, 2012. doi:  10.1186/1471-2407-12-111
PMCID: PMC3350382
miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10
Yating Chen,#1 Jin Zhang,#1 Huijun Wang,2 Jiayi Zhao,1 Cheng Xu,3 Yingying Du,1 Xin Luo,1 Fengyun Zheng,4 Rui Liu,1 Hongwei Zhang,corresponding author3 and Duan Macorresponding author1,2,4
1Key Laboratory of Molecular Medicine, Ministry of Education, Shanghai Medical College, Fudan University, Shanghai 200032, China
2Children"s Hospital of Fudan University, Shanghai 201102, China
3Department of Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4Institutes of Biomedical Science, Fudan University, Shanghai 200032, China
corresponding authorCorresponding author.
#Contributed equally.
Yating Chen: yatingch99/at/hotmail.com; Jin Zhang: jeanzhj/at/gmail.com; Huijun Wang: huijunwan/at/fudan.edu.cn; Jiayi Zhao: 0556126/at/fudan.edu.cn; Cheng Xu: xucheng/at/live.cn; Yingying Du: safireto1982/at/gmail.com; Xin Luo: luoxin_lx/at/yahoo.com.cn; Fengyun Zheng: zhengfengyun/at/gmail.com; Rui Liu: ruiliu1221/at/gmail.com; Hongwei Zhang: zhang.hongwei/at/zs-hospital.sh.cn; Duan Ma: duanma/at/shmu.edu.cn
Received November 4, 2011; Accepted March 23, 2012.
Background
miRNAs are a group of small RNA molecules regulating target genes by inducing mRNA degradation or translational repression. Aberrant expression of miRNAs correlates with various cancers. Although miR-135a has been implicated in several other cancers, its role in breast cancer is unknown. HOXA10 however, is associated with multiple cancer types and was recently shown to induce p53 expression in breast cancer cells and reduce their invasive ability. Because HOXA10 is a confirmed miR-135a target in more than one tissue, we examined miR-135a levels in relation to breast cancer phenotypes to determine if miR-135a plays role in this cancer type.
Methods
Expression levels of miR-135a in tissues and cells were determined by poly (A)-RT PCR. The effect of miR-135a on proliferation was evaluated by CCK8 assay, cell migration and invasion were evaluated by transwell migration and invasion assays, and target protein expression was determined by western blotting. GFP and luciferase reporter plasmids were constructed to confirm the action of miR-135a on downstream target genes including HOXA10. Results are reported as means ± S.D. and differences were tested for significance using 2-sided Student"s t-test.
Results
Here we report that miR-135a was highly expressed in metastatic breast tumors. We found that the expression of miR-135a was required for the migration and invasion of breast cancer cells, but not their proliferation. HOXA10, which encodes a transcription factor required for embryonic development and is a metastasis suppressor in breast cancer, was shown to be a direct target of miR-135a in breast cancer cells. Our analysis showed that miR-135a suppressed the expression of HOXA10 both at the mRNA and protein level, and its ability to promote cellular migration and invasion was partially reversed by overexpression of HOXA10.
Conclusions
In summary, our results indicate that miR-135a is an onco-miRNA that can promote breast cancer cell migration and invasion. HOXA10 is a target gene for miR-135a in breast cancer cells and overexpression of HOXA10 can partially reverse the miR-135a invasive phenotype.
Micro RNAs (miRNAs) are small non-coding, cellular RNAs (17-27 bp) that post-transcriptionally regulate gene expression by inducing the degradation or translational repression of target mRNAs. The discovery of miRNAs and their mode of action has revealed an entirely new level of gene regulation. miRNAs must be assembled into a complex termed the RNA induced silencing complex (RISC) in order to regulate expression of their mRNA targets. Once assembled they act by binding to the 3'untranslated region (3'-UTR) and inducing degradation or transcriptional repression [1]. An individual miRNA is capable of regulating hundreds of distinct mRNAs, and more than 1,000 human miRNAs have been identified that could potentially modulate close to one-third of the coding genes in human genome [2].
Aberrant expression of miRNAs has been correlated with various human diseases including cancers. miRNAs have been identified which have oncogenic or tumor suppressor properties because the target genes they regulate are oncogenes or tumor suppressor genes. The abnormal expression profiles of miRNAs have been examined in many different cancers including breast cancer [3,4] and their roles in the proliferation, apoptosis, invasion/metastasis and angiogenesis of normal and cancer cells are being investigated aggressively [5-9].
The function of the miRNA miR-135a is currently under investigation in our laboratory. Processes known to be under the control of miR-135a include megakaryocytopoiesis[10], bone and muscle development, hypertension, colorectal cancer through its target gene Adenomatous Polyposis Coli (APC)[11-13], epithelial ovarian cancer and endometriosis through its target gene HOXA10[14], portal vein tumor thrombus through its target gene metastasis suppressor 1 and Hodgkin disease and gastric cancer through its target JAK2[15,16]. At present however, its role in breast cancer is unknown.
Normal development and tumorigenesis both depend on shifts in the delicate balance between cell growth and differentiation. Altered expression of genes that are involved in the transcriptional control of developmental pathways often contribute significantly to oncogenesis because cancer can arise from the misappropriation of signalling pathways normally used to control cell fate [17]. The Homeobox genes encode transcription factors that are critical for the proper placement of segment structures during embryonic development. Analysis of numerous tumors have revealed that the expression of specific HOX genes is often increased or decreased, indicating that they can influence tumor suppression or tumor development, invasion, and metastasis [18]. Several HOX genes have been shown to be partially regulated by miRNAs [6,19-21], indicating the potential for oncogenic pathways that begin with miRNA dysregulation, leading to altered HOX gene expression and ultimately tumorigenesis or tumor suppression. The HOXA10 gene is a regulator of embryonic morphogenesis and differentiation and is aberrantly expressed in several types of cancers [22-29]. Recently it was reported to induce p53 expression in breast cancer cells and to reduce their invasiveness [30]. Of specific interest, HOXA10 has been shown to be under the control of miR-135a in endometrial and epithelial cancer tissues [14] which led us to ask if miR-135a might also be associated with breast cancer.
In this study, we found that miR-135a levels are elevated in breast cancer with metastasis. By manipulating the expression level of miR-135a in vitro, we showed that miR-135a could promote the migration and invasiveness of breast cancer cells. We used bioinformatic tools and the literature to identify HOXA10 as a miR-135a target gene candidate and verified it is directly regulated by miR-135a in breast cancer cells. We found that over expression of HOXA10 could partially reduce the invasive property mediated by elevated miR-135a levels in the breast cancer cell line BT549.
Cell culture and tissue samples
All cell lines were obtained from the American Type Culture Collection. HEK293, human breast cancer cell lines BT549, SKBr3 and MDA-MB-231 were cultured in Dulbcco"s Modifed Eagle Medium (Gibco, Grand Island, NY, USA). All cell lines were incubated at 37°C in 5% CO2. Patients samples are collected from Zhongshan Hospital, Fudan University. This research was taken under consent of all patients for the use of their samples. This program is got approval by the Institute of Biomedical Sciences ethics committee of Fudan University. Ten Benign patient diagnosed as adenosis or fibroadenoma, fifteen invasive breast cancer as malignant samples whose ER(-), PR(-) and CerbB-2 (-) markers are all negative and all have lymph node metastasis. Fresh tissue samples were harvested from patients, and preserved at -80°C.
Detection of mRNAs and miRNAs
Total RNA from cells and human tissue samples were extracted using Trizol (Invitrogen) according to the manufacturer"s instructions and 2 μg of each total RNA sample was aliquoted to synthesize cDNA using the Reverse Transcription System (Promega). For mRNA detection and expression, HOXA10 and β-actin were analyzed by RT-PCR or qRT-PCR. All qRT-PCR products were amplified using a SYBR green PCR Master Mix kit (Qiagen) according to the manufacturer"s instructions on the ABI Prism 7,500 Detection System (Applied Biosystems). For quantification of HOXA10 mRNA in transfected cells, β-actin was used as the internal control. Levels of mRNA were quantified based on the ratio of HOXA10 mRNA/β-actin mRNA using the 2 - ΔΔCt method where ΔΔCt = ΔCtexp - ΔCtnc = (Ctexp-target - Ctexp-actin) - (Ctnc-target - Ctnc-actin), in which "exp" represents the experimental group, "nc" the negative control group, and "target" the gene of interest.
For miRNA detection, we employed Poly (A) RT-PCR method using specific forward primers and a universal reverse primer complementary to an anchor primer as previously described [31]. The anchor RT primer was used as the template for the negative control and the U6 small nuclear RNA was used as the control to determine relative miRNA expression. Levels of miR-135a in human tissue samples were quantified and normalized to 18S rRNA using the 2 - ΔΔCt method formula as described above. The PCR profile was one cycle of 95°C for 5 min, then 40 cycles of 95°C for 5 s and 60°C for 50 s. The primers used for detection are listed in Table Table11.
Table 1
Table 1
Primers for detection of HOXA10 mRNA and miR-135a by RT-PCR
Plasmid construction and transfection
A DNA fragment encoding the miR-135a pre-miRNA was amplified by PCR from HEK293 genomic DNA and cloned into a modified pSilencer 4.1-CMVneo vector (Ambion) as previously described [31]. Positive clones were identified by PCR screening and DNA sequencing. Using genomic similarly, 3"-UTRs from the predicted mir-135a target genes HOXB7, APC and HOXA10 were PCR amplified from HEK293 DNA and cloned into the XbaI site immediately downstream of the stop codon in the pGL3-promoter vector (Promega). To produce mutant HOXA10 3'-UTR pGL3-reporter plasmids, the predicted miR-135a binding sites were replaced with 18 bp-long fragments (Table (Table2)2) by overlapping PCR. Fragments of HOXA10 containing 3' UTR regions were cloned from a HOXA10 cDNA into pEGFP-C1 for pEGFP-HOXA10 plasmid construction. The HOXA10 expression vector pcDNA3-hisC-HOXA10 and vector pcDNA-HOXA10-de-3'UTR were kindly provided by Dr Herring (Indiana University, USA). The miR-135a anti-sense oligonucleotide inhibitor (miR-135a inhibitor) and a mismatched sequence (N.C) were purchased from GenePharma (Shanghai, China). HOXA10 and Control siRNAs were from Santa Cruz (sc-38685, sc-37007). The primers used were listed in Table Table2.2. All plasmid DNAs used for transfection were prepared using a Qiagen DNA Miniprep kit following the manufacturer"s instructions. Cells were transiently transfected with vectors or anti-miR inhibitor using Lipofectamine 2000 from Invitrogen (CA, USA) according to the manufacturer"s instructions.
Table 2
Table 2
Sequences of PCR primers for plasmid construction
In vitro luciferase assay
HEK293 cells (1 × 105) were seeded into a 96-well plate and co-transfected with 5 ng of internal control vector pRL-renilla (Promega), 50 ng of a pGL3-promoter reporter with either the HOXA10, mutant HOXA10, HOXB7 or APC 3'-UTR and 150 ng of the pSilencer-135a (pS-135a) or pSilencer-4.1-CMV-negative (pS-negative) vector. Forty eight hours after transfection, the firefly and Renilla luciferase activities were assayed using the Dual-Glo Luciferase assay system from Promega according to the manufacturer"s protocol. For each sample firefly luciferase activity was normalized to the Renilla luciferase activity value.
Western blotting
Whole-cell extracts were prepared using RIPA lysis buffer and SDS-PAGE followed by Western blotting were performed as previously described [31] and signals were visualized with Super Signal West Femto chemiluminescent substrate. For each condition, samples were analyzed three times independently. The primary antibodies used were from Santa Cruz Biotechnologies for HOXA10 (sc-28602), Sigma for β-actin (A7441), and Cell Signaling for GFP (#2956). The peroxidase-conjugated anti-mouse or anti-rabbit IgG secondary antibodies were from Santa Cruz Biotechnology.
Cell proliferation assay
MDA-MB-231 or BT549 (1 × 104 cells per well) were plated into 96-well plates in triplicate prior to pSilencer 4.1-CMV-135a or pS-negative transfection and then cultured for approximately 16 h. Cell proliferation was assessed 72 h after transfection using CCK8 (Dojindo, Tokyo, Japan) according to the manufacturer"s instructions.
Migration and invasion assay
Cell migration and invasive ability was examined using a 24-well transwell plate with 8 mm pore polycarbonate membrane inserts, according to the manufacturer"s protocol (Corning, NY, USA). The matrigel (14.8 μg/ml) employed for the invasion assays was applied to the upper surface of the membranes. Forty eight hours after transfection, 5 × 104 cells per well were seeded into the top chamber in serum-free media and this was replaced with complete growth media for 12 h. Cells that migrated or invaded through surface of the membrane were fixed with methanol and stained with hematoxylin. Migrating or invasive cells from three random microscope fields per filter were selected for cell counting.
Bioinformatics prediction and statistics analysis
We computationally screened proper targets for miR-135a by miRNAMap http://mirnamap.mbc.nctu.edu.tw/. Statistical analysis for miR-135a expression in tissues was performed using a Jonckheere-Terpstra exact test for trend to compare the distribution of expression levels (high, medium, low, none) across breast tumors and benign tissues. A Bonferroni adjustment was applied to the p values for the pair-wise comparisons. Results were delineated as means ± S.D., differences were tested for significance using 2-sided Student"s t-test.
miR-135a levels were elevated in human metastatic breast tumors
Expression levels of miR-135a were detected from 30 human primary breast tumor samples using poly (A)-RT-PCR, as previously described [31]. The patient samples in our study we choose have very similar clinico-pathological features. We choose benign breast samples diagnosed as adenosis or fibroadenoma, and choose "triple negative" invasive breast cancer as malignant samples whose ER(-), PR(-) and CerbB-2 (-) markers are all negative and have lymph node metastasis, the prognosis of these patients are relative bad. We found that the average miR-135a level was higher in the „triple negative" malignant invasive tumors than that in the benign tumors (Figure (Figure1A).1A). The expression levels of miR-135a in breast cancer cell lines that included T47d, MCF-7, SKBr3, MDA-MB-231, and BT549 were also examined. We found that miR-135a was up-regulated in breast cancer cell line BT549 which has a highly invasive phenotype (Figure (Figure1B1B).
Figure 1
Figure 1
Expression of miR-135a was elevated in human breast tumors with metastasis. (A) miR-135a levels were detected in 30 human breast samples by SYBR Green qRT-PCR with 18S rRNA used as a loading control. For benign tumors (adenosis or fibroadenoma) n = 10 (more ...)
miR-135a increased breast cancer cells migration and invasion properties
Cell invasion is a significant aspect of cancer progression which involves the migration of tumor cells into contiguous tissues and the dissolution of extracellular matrix proteins [7]. Because we found that miR-135a was highly expressed in the „triple negative" malignant invasive human tumors and the BT549 tumor line, which has a highly invasive phenotype, we asked if miR-135a overexpression contributed to these phenotypes. We transfected BT549 cells with miR-135a inhibitor (2'-O-methylated oligonucleotides) to block miR-135a action and performed a migration assay with the cells 48 h after transfection. The miR-135a inhibitor impeded the migration of BT549 cells from serum-free medium to serum-containing medium, reducing it by 2-fold (Figure (Figure2A).2A). In addition, the invasion of miR-135a inhibitor transfected BT549 cells was also significantly compromised (Figure (Figure2A).2A). These effects appear to be specifically attributable to the miR-135a inhibitor blocking the biological action of miR-135a because the NC mismatched control inhibitor failed to affect either migration or invasion.
Figure 2
Figure 2
miR-135a increased breast cancer cells migration and invasion properties. (A) Migration and invasion after transfection of BT549 cells with a miR-135a inhibitor or no inhibitor (N.C.). Images of invasive BT549 cells (left panel). (B) Migration and invasion (more ...)
Because the inhibition of miR-135a reduced BT549 cell migration and invasion, we assessed the effect of miR-135a overexpression in cell lines SKBr3 and MCF-7 using a pSilencer-135a vector (see Methods). The forced expression of miR-135a resulted in a ~2-fold increase of SKBr3 cell migration (Figure (Figure2B).2B). Consistent with this result, the invasive activity of SKBr3 cells across an extracellular matrix also increased. But no change on migration and invasive activity was observed in MCF-7 cells (data not shown). To confirm that the ability of miR-135a to promote cell migration and invasion was not restricted to SKBr3 cells, we tested a third human breast cancer cell line, MDA-MB-231. The migration and invasive activity of these cells was also enhanced by overexpressing miR-135a (Figure (Figure2C),2C), suggesting that miR-135a function can promote migration and invasion in breast cancer cells.
We also tested if miR-135a could affect cancer cell proliferation by overexpression, down-regulation or both. The results demonstrated that altered miR-135a expression neither increased nor decreased cell growth compared to control cells (Figure (Figure2D).2D). In summary, our data indicates that miR-135a can increase breast cancer cell migration and invasiveness, but has no obvious effect on cell proliferation.
HOXA10 is a direct target of miRNA-135a in breast cancer cells
We used miRNAMap online http://mirnamap.mbc.nctu.edu.tw/ to predict the targets of miR-135a, we chose HOXA10 for further analysis because of its relatively high prediction score, and complementary structure with miRNA-135a (Figure (Figure3A).3A). To verify HOXA10 is a real target of miR-135a in breast cancer, we first tested if HOXA10 is co-expressed with this miRNA. HOXA10 mRNA levels were measured by RT-PCR in HEK293, HUVEC, HBL-100 and several breast cancer cell lines. We found HOXA10 was indeed expressed in most breast cancer cell lines except MDA-MB-231 (Figure (Figure3B).3B). We next tested if miR-135a could repress HOXA10 using an in vitro luciferase reporter assay. Plasmid DNA of pGL3-promoter based 3'-UTR reporter constructs were co-transfected with pSilencer4.1CMV-135a (pS-135a) or the pSilencer4.1CMV-negative control (pS-negative or pS-N). As a positive control for miR-135a activity we used a, pGL3-APC 3'-UTR construct and used a pGL3- HOXB7 3'-UTR construct as a negative control. Coexpression of the HOXA10 luciferase reporter with miR-135a greatly reduced the luciferase activity. And this effect was largely eliminated when the sites in HOXA10 3'-UTR targeted by miR-135a were mutated (Figure (Figure3C).3C). Conversely, co-transfected miR-135a inhibitor with pGL3- HOXA10 3'-UTR in BT549 cells, which express miRNA-135a endogenously, increased luciferase activity (Figure (Figure3D).3D). These observations suggested that HOXA10 is a direct target of miRNA-135a.
Figure 3
Figure 3
HOXA10 as a target of miR-135a. (A) Online prediction of miR-135a potential binding sites on HOXA10 3'-UTR. The nucleotide sequence illustrates the predicted base-pairing between miR-135a and the HOXA10 3'-UTR. (B) The endogenous mRNA expression of HOXA10 (more ...)
Next, we used HEK293 cells because they expressed HOXA10 endogenously (Figure (Figure3B),3B), but expressed minimal level of miR-135a (Figure (Figure1B),1B), providing a good cell model system to determine the relationship between miR-135a and HOXA10 expression in vitro. Co-expression of pEGFP-HOXA10 with the pSilencer-135a in HEK293 cells led to a decreased expression of the GFP-HOXA10 fusion protein compared to the negative control (Figure (Figure4A).4A). In addition, introducing miR-135a by transfection of pS-135a into HEK293 cells reduced the endogenous HOXA10 protein expression (Figure (Figure4B).4B). We also detected a decrease of endogenous HOXA10 mRNA by real-time RT-PCR 48 h after transfecting HEK293 cells with pS-135a (Figure (Figure4C).4C). So we believe that miRNA-135a regulates HOXA10 expression at both protein and mRNA levels. In breast cancer cell lines, expressing miR-135a by transfection of pS-135a reduced the endogenous HOXA10 protein expression in MCF-7 cells (Figure (Figure4D)4D) and BT549 cells (Figure (Figure4E).4E). Besides, inhibition of miR-135a in BT549 cells increased HOXA10 protein expression (Figure (Figure4E).4E). These findings strongly indicate that HOXA10 is a target of miR-135a in breast cancer cells.
Figure 4
Figure 4
miR-135a regulation of HOXA10 expression. (A) Images of GFP-labeled HEK293 cells (left panel). Western blot of GFP protein in GFP-labeled HEK293 cells (right panel). Anti-GAPDH antibody was used as a loading control (bottom panel). The HEK293 cells were (more ...)
Overexpression of HOXA10 partially reversed the invasive property of BT549 cells caused by miR-135a
To test whether HOXA10 regulation contributed to effect of miR-135a on migration and invasion, we cotransfected miR-135a (or negative control) and a vector pcDNA-HOXA10-mu-3'UTR containing HOXA10, mutated in the miR-135a binding site in the 3'-UTR into MDA-MB-231 cells, and found that HOXA10"s role of suppressing cell invasiveness was not limited by miR-135a when the sites in HOXA10 3'-UTR targeted by miR-135a were mutated. Besides, overexpressing HOXA10 with either pcDNA-HOXA10 or pcDNA-HOXA10-mu-3'UTR vector decreased invasiveness of MDA-MB-231 cells (Figure (Figure5A).5A). Conversely, downexpressing HOXA10 increased the invasive property of BT549 cells (Figure (Figure5B).5B). In addition to MDA-MD-231, the similar rescue experiment was carried out in BT549 cells. Compared with miR-135a knockdown alone, double knockdown of miR-135 and HOXA10 in BT549 could partially rescue the decreased invasive property caused by 135a inhibitor (Figure (Figure5B5B).
Figure 5
Figure 5
Expression of HOXA10 reversed cell invasive property caused by miR-135a in BT549 cells. (A) Invasion assay of MDA-MB-231 cells 48 h after cotransfecting pS-135a or pS-negative and pcDNA HOXA10 contains a full-length HOXA10 cDNA, or pcDNA HOXA10-mu-3'UTR, (more ...)
We then transfected BT549 cells with HOXA10-expressing vectors that included a 3'-UTR deleted gene (pcDNA HOXA10-de-3'UTR), a full-length HOXA10 positive control (pcDNA HOXA10) and a negative control (pcDNA negative). Western blot analysis showed that the level of the HOXA10 protein expressed from the construct lacking the HOXA10 3'-UTR was the highest compared to the cells transfected with vectors containing the full-length HOXA10 cDNA or the negative control (Figure (Figure5C).5C). Invasion assays on BT549 cells showed that overexpression of HOXA10 reversed the effect of miR-135a on invasion by at least 40% (Figure (Figure5D).5D). However, in the BT549 cells which express high levels of endogenous miR-135a over-expression of HOXA10 protein by the pcDNA HOXA10 was decreased compared to the amount expressed by pcDNA HOXA10-de-3'UTR which carries the HOXA10 3'-UTR deletion, and its effect on suppressing invasion was also less strong. Since miR-135a is expressed endogenously in BT549 cells, it is likely that endogenous miR-135a inhibits HOXA10 overexpression by targeting its 3'UTR. Moreover, consistent with invasion assay of BT549 cells transfected with miR-135a inhibitor, overexpression of HOXA10 impaired the invasion of BT549 cells.
miRNAs are small noncoding regulatory RNAs that have been studied in various types of cancers. Many miRNAs that regulate epithelial to mesenchymal transition (EMT) [32] and pro-metastatic [5,6] or anti-metastatic functions [9] have been identified. Previously miR-135 has been reported to regulate genes in many other types of cancer [11,14,16,33,34], but its roles in breast cancer was unknown. Our current study provides the first evidence to demonstrate that miR-135a plays a role in promoting migration and invasion of breast cancer cells.
The ability of miR-135a to promote cell migration and invasion was assessed by both over-expression and down-regulation experiments. Remarkably, we observed apparent high levels of miR-135a expression in „triple negative" malignant invasive breast tumors (Figure (Figure1A),1A), and the highly invasive phenotype of the BT549 cell line (Figure (Figure1B),1B), suggesting that miR-135a might play an important role in maintaining metastatic functions. This hypothesis is supported by our experiments showing that inhibition of miR-135a activity impaired the invasion and migration of BT549 cells in vitro (Figure (Figure2A).2A). To further verify, this relationship up-regulation experiments were performed in cell lines with different invasive phenotypes. In addition to the enhanced migration and invasive ability of SKBr3 cells induced by increased miR-135a expression (Figure (Figure2B),2B), we also observed enhanced invasive ability of miR-135a-transfected MDA-MB-231 cells (Figure (Figure2C).2C). Although endogenous miR-135a was not detectable in MDA-MB-231 cells they are highly invasive, and we speculate that migration and invasion may not be miR-135a-dependent processes in those cells due to genetic differences between different breast cancer cell lines. Furthermore, miR-135a could not affect the low invasive property of MCF-7 cells even though it was forced overexpressed and led to decreased endogenous HOXA10 protein expression in those cells (Figure (Figure4D).4D). We speculate this is also due to genetic cell specificity. For example, E-cadherin is highly expressed in MCF-7, so we believe that the effect of miR-135a over-expression is not strong enough to induce a change of the migration status of the MCF-7 cells. This suggests that the native non-metastatic character of MCF-7 may have other miR-135a-independent mechanisms that are responsible to maintain the non-aggressiveness of this particular cell type. It is also possible that HOXA10 3'UTR is mutated and cannot be targeted by miR-135a in MCF-7 cells. Future studies are required to define these two possibilities. Indeed it has been reported that HOXA10 is not regulated by miR-135a in MCF-7 cells [14] which is in contrast to our results for other cancer cell lines tested. Unlike the migration and invasion phenotypes, up- or down-regulation of miR-135a did not affect cell proliferation (Figure (Figure2D2D).
Several HOX genes are regulated by miRNAs [6,19-21]. This work is the first to implicate miR-135a down-regulation of HOXA10 expression in breast cancer cell invasiveness. The mechanism by miR-135a targets HOXA10 for repression was verified by in vitro 3'-UTR luciferase assays. HOXA10 over-expression in miR-135a expressing cells was dependent on the absence of the HOXA10 3'-UTR (Figure 3C-D) supporting our conclusion that miR-135a inhibits HOXA10 via targeting its 3'-UTR. Our results showed that endogenous HOXA10 in MDA-MB-231 was not detectable (Figure (Figure3B)3B) and this could be attributable to methylation of the HOXA10 promoter as previously reported [35]. Combined with the fact that individual miRNAs have the potential to modulate the expression of many mRNAs, our result showing miR-135a expression in MDA-MB-231 cells that increased migration and invasion (Figure (Figure2C)2C) suggest there may be miR-135a targets other than HOXA10 that can promote migration/invasion events. Indeed, miR135a was reported to be up-regulated in portal vein tumor thrombus and these cells showed increased migration and invasion in vitro. However, the metastasis suppressor 1 gene and not HOXA10 was found to be the direct, functional target of miR-135a in this tissue [16]. We propose that this gene may function in some breast cancers to suppress migration and invasion rather than HOXA10, and we intend to test this in the near future. Our results also suggested that miR-135a post-transcriptional down-regulation of the HOXA10 target gene was not restricted to translation repression (Figure 4A-B, 4D-E) but also occurred by inducing mRNA degradation (Figure (Figure4C),4C), which agrees with previous reports on the action of miRNAs and highly homologous targets [36].
To further investigate the effect of HOXA10 on breast cancer cell invasiveness, we overexpressed HOXA10 in already highly invasive breast cancer cell lines. Overexpression of HOXA10 without 3' UTR targeting by miR-135a led to decreased invasion of MDA-MB-231 cells (Figure (Figure5A),5A), and significantly inhibited the miR-135a-regulated invasion of BT549 cells (Figure (Figure5D).5D). Knockdown of HOXA10 increased invasiveness of BT549 cells and could partially rescue the decreased invasive property caused by 135a inhibitor (Figure (Figure5B).5B). Other members in the same gene family have also been shown to play roles in breast cancer. It has previously been reported that HOXA9, a paralog of HOXA10, is a tumor suppressor in breast cancer [37], and expression of HOXD10 in MDA-MB-231 significantly impaired migration [38]. Interestingly, in BT549 cells the expression of a full-length HOXA10 cDNA was repressed. It is highly likely that the high endogenous miR-135a level inhibits HOXA10 expression through targeting its 3'-UTR, since deletion of 3'-UTR led to a higher expression of HOXA10 protein than the full-length cDNA HOXA10 (Figure (Figure5C),5C), and the effect of HOXA10 overexpression on cell invasion varied depending on the absence or presence of the HOXA10 3'-UTR (Figure (Figure5D).5D). These results illustrate that miR-135a promoted cell migration and invasion, at least partially, through repression of HOXA10 via its 3'-UTR and also verified the in vitro luciferase assay results (Figure 3C-D). However, there is no evidence that miR-135a regulation of HOXA10 is exclusive. HOXA10 may also be targeted by other miRNAs and it appears that promoter methylation is also an important regulatory mechanism for HOXA10 in some tissues [35,39]. Our result is in an agreement with a former study that reported HOXA10 expression inhibited matrigel invasion by breast cancer cells [30]. The study also reported that HOXA10 expression induced p53 production. Therefore, understanding the molecular mechanism of the regulation of HOXA10 by miR-135a may provide a method to explore upstream regulation of HOXA10 and connect it with p53 tumor suppressor signalling pathways in breast cancer. Also, the "triple negative" invasive breast cancer type has a very poor prognosis and as yet no antibody target has been reported for the treatment of this type of breast cancer. So we believe future investigation on in vivo studies as well as on clinical specimens will confirm the importance of miR-135 and identify additional markers for diagnosis and treatment.
Although further work is required to fully understand the mechanism by which miR-135a influences tumor metastasis in vivo, the identification of miR-135a as a regulator of tumor migration and invasion in vitro suggests it may play an important role in mediating the oncogenesis of breast cancer. Our results indicate that miR-135a levels can regulate breast cancer cell migration and invasion, but not proliferation, at least partly through 3'-UTR targeting and repression of HOXA10 expression. Furthermore, given the apparent high levels of miR-135a in the „triple negative" malignant metastatic breast cancers, inhibitory targeting of miR-135a may have therapeutic potential for controlling or preventing breast tumor metastasis.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YC carried out the experimental studies, drafted and completed the manuscript. JZ set up the method called Poly (A) RT PCR for miRNA detection and participated in the design of the study. HW was in charge of the clinical samples selection and performed the proofreading. ZJ, CX, YD and LX disposed the tissue samples. FZ and JZ completed sample conservation. RL refined the manuscript. HZ and DM conceived of the study and performed the statistical analysis. All authors read and approved the final manuscript.
Pre-publication history
The pre-publication history for this paper can be accessed here:
Acknowledgements
This paper was supported by National Science Fund for Fostering Talents in Basic Science (J0730860) and Key Projects in the National Science & Technology Pillar Program in the Eleventh Five-year Plan Period (2006BAI05A05). We thank Dr. B. Paul Herring (Indiana University, USA) for providing HOXA10 expression vectors pcDNA3-hisC-HOXA10 and pcDNA-HOXA10-de-3'UTR. We deeply appreciate Dr. Margaret Morgan (City of Hope, USA) and Dr. Xiangli Yang (Vanderbilt University, USA) for critically reviewing the manuscript.
  • Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Sci. 2010;101:2309–2315. doi: 10.1111/j.1349-7006.2010.01683.x. [PubMed] [Cross Ref]
  • Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233. doi: 10.1016/j.cell.2009.01.002. [PubMed] [Cross Ref]
  • Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO. et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007;8:R214. doi: 10.1186/gb-2007-8-10-r214. [PMC free article] [PubMed] [Cross Ref]
  • Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA. et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–838. doi: 10.1038/nature03702. [PubMed] [Cross Ref]
  • Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ. et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008;10:202–210. doi: 10.1038/ncb1681. [PubMed] [Cross Ref]
  • Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–688. doi: 10.1038/nature06174. [PubMed] [Cross Ref]
  • Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–152. doi: 10.1038/nature06487. [PMC free article] [PubMed] [Cross Ref]
  • Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27:2128–2136. doi: 10.1038/sj.onc.1210856. [PubMed] [Cross Ref]
  • Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009;137:1032–1046. doi: 10.1016/j.cell.2009.03.047. [PMC free article] [PubMed] [Cross Ref]
  • Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G. et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci USA. 2006;103:5078–5083. doi: 10.1073/pnas.0600587103. [PubMed] [Cross Ref]
  • Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA, Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008;68:5795–5802. doi: 10.1158/0008-5472.CAN-08-0951. [PubMed] [Cross Ref]
  • Li Z, Hassan MQ, Volinia S, van Wijnen AJ, Stein JL, Croce CM, Lian JB, Stein GS. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci USA. 2008;105:13906–13911. doi: 10.1073/pnas.0804438105. [PubMed] [Cross Ref]
  • Pang RT, Liu WM, Leung CO, Ye TM, Kwan PC, Lee KF, Yeung WS. miR-135A regulates preimplantation embryo development through down-regulation of E3 Ubiquitin Ligase Seven In Absentia Homolog 1A (SIAH1A) expression. PLoS One. 2011;6:e27878. doi: 10.1371/journal.pone.0027878. [PMC free article] [PubMed] [Cross Ref]
  • Petracco R, Grechukhina O, Popkhadze S, Massasa E, Zhou Y, Taylor HS. MicroRNA 135 Regulates HOXA10 Expression in Endometriosis. J Clin Endocrinol Metab. 2011;96:E1925–1933. doi: 10.1210/jc.2011-1231. [PubMed] [Cross Ref]
  • Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, Codony C, Ferrer G, Martinez C, Montserrat E, Monzo M. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009;114:2945–2951. doi: 10.1182/blood-2009-02-204842. [PubMed] [Cross Ref]
  • Liu S, Guo W, Shi J, Li N, Yu X, Xue J, Fu X, Chu K, Lu C, Zhao J, MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol. 2011. [PubMed]
  • Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer. 2002;2:777–785. doi: 10.1038/nrc907. [PubMed] [Cross Ref]
  • Takahashi O, Hamada J, Abe M, Hata S, Asano T, Takahashi Y, Tada M, Miyamoto M, Kondo S, Moriuchi T. Dysregulated expression of HOX and ParaHOX genes in human esophageal squamous cell carcinoma. Oncol Rep. 2007;17:753–760. [PubMed]
  • Shen WF, Hu YL, Uttarwar L, Passegue E, Largman C. MicroRNA-126 regulates HOXA9 by binding to the homeobox. Mol Cell Biol. 2008;28:4609–4619. doi: 10.1128/MCB.01652-07. [PMC free article] [PubMed] [Cross Ref]
  • Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, Souidi M, Cuvellier S, Harel-Bellan A. The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol. 2006;8:278–284. doi: 10.1038/ncb1373. [PubMed] [Cross Ref]
  • Woltering JM, Durston AJ. MiR-10 represses HoxB1a and HoxB3a in zebrafish. PLoS One. 2008;3:e1396. doi: 10.1371/journal.pone.0001396. [PMC free article] [PubMed] [Cross Ref]
  • Hung YC, Ueda M, Terai Y, Kumagai K, Ueki K, Kanda K, Yamaguchi H, Akise D, Ueki M. Homeobox gene expression and mutation in cervical carcinoma cells. Cancer Sci. 2003;94:437–441. doi: 10.1111/j.1349-7006.2003.tb01461.x. [PubMed] [Cross Ref]
  • Lawrence HJ, Sauvageau G, Ahmadi N, Lopez AR, LeBeau MM, Link M, Humphries K, Largman C. Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells. Exp Hematol. 1995;23:1160–1166. [PubMed]
  • Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N, Feng Y. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer. 2009;19:1347–1352. doi: 10.1111/IGC.0b013e3181a83f1d. [PubMed] [Cross Ref]
  • Cheng W, Jiang Y, Liu C, Shen O, Tang W, Wang X. Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer. J Cancer Res Clin Oncol. 2010. [PubMed]
  • Cheng W, Liu J, Yoshida H, Rosen D, Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med. 2005;11:531–537. doi: 10.1038/nm1230. [PubMed] [Cross Ref]
  • Yamatoji M, Kasamatsu A, Yamano Y, Sakuma K, Ogoshi K, Iyoda M, Shinozuka K, Ogawara K, Takiguchi Y, Shiiba M. et al. State of homeobox A10 expression as a putative prognostic marker for oral squamous cell carcinoma. Oncol Rep. 2010;23:61–67. [PubMed]
  • Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E. et al. Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci USA. 2000;97:12776–12781. doi: 10.1073/pnas.97.23.12776. [PubMed] [Cross Ref]
  • Lane DB, Rutherford TJ, Taylor HS. HOXA10 expression in endometrial adenocarcinoma. Tumour Biol. 2004;25:264–269. doi: 10.1159/000081390. [PubMed] [Cross Ref]
  • Chu MC, Selam FB, Taylor HS. HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells. Cancer Biol Ther. 2004;3:568–572. [PubMed]
  • Zhang J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ, Ma D. The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun. 2008;377:136–140. doi: 10.1016/j.bbrc.2008.09.089. [PubMed] [Cross Ref]
  • Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601. doi: 10.1038/ncb1722. [PubMed] [Cross Ref]
  • Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, Parissenti A, Duan Z, Voest EE, Zetter BR. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene. 2011;30:4386–4398. doi: 10.1038/onc.2011.148. [PubMed] [Cross Ref]
  • Wu S, Lin Y, Xu D, Chen J, Shu M, Zhou Y, Zhu W, Su X, Qiu P, Yan G. MiR-135a functions as a selective killer of malignant glioma. Oncogene. 2011. [PubMed]
  • Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE. et al. Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci USA. 2008;105:14076–14081. doi: 10.1073/pnas.0805206105. [PubMed] [Cross Ref]
  • Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem. 2009;284:31921–31927. doi: 10.1074/jbc.M109.046862. [PubMed] [Cross Ref]
  • Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK, HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest. 2010. [PMC free article] [PubMed]
  • Carrio M, Arderiu G, Myers C, Boudreau NJ. Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. Cancer Res. 2005;65:7177–7185. doi: 10.1158/0008-5472.CAN-04-1717. [PubMed] [Cross Ref]
  • Yoshida H, Broaddus R, Cheng W, Xie S, Naora H. Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial-mesenchymal transition. Cancer Res. 2006;66:889–897. doi: 10.1158/0008-5472.CAN-05-2828. [PubMed] [Cross Ref]
Articles from BMC Cancer are provided here courtesy of
BioMed Central